Blue Horseshoe Stocks: ESPR Highlights & Much More

Yesterday, on a day when the market as a whole was faltering, we’re proud to say we managed to bring our readers several opportunities to gain in both stocks and options:

Esperion Therapeutics, Inc. ESPR- Options Ideas

ESPR turned out to be a great call for us in yesterday’s morning report. The stock itself made an impressive session-long move from a low of 82.69 up to 100.50 (+22%), resulting in some monstrous spikes for the options ideas we highlighted.

We raised a flag of interest on in-the-money Weekly Calls, and were rewarded with mega-spikes across the board:

$80 Calls – Trading Range: 4.00-20.00  Max Gain: 400%
$85 Calls – Trading Range: 2.15-14.50  Max Gain: 574%
$90 Calls – Trading Range: .70-14.50  Max Gain: 1400%
$95 Calls – Trading Range: .64-7.25  Max Gain: 1032%

Even the play we designated as a longer-term selection, the 04/17 $90 Calls, were immediately and significantly impacted, trading in a range from 3.50-14.50. That move was good for intraday gains of up to 314%


As far as our other options calls were concerned, we met with success there as well:

American Airlines Group Inc. AALFor AAL, we zeroed in on the 04/02 $55 Calls which ended up trading up from .79, to as high as 1.11, marking a 40% intraday gain. Any other contracts that got pushed into the money would have also provided excellent opportunities for successful day-trades.

Apple, Inc. AAPL – On AAPL, we mentioned that we’d be watching the 04/02 $129 Calls and those made a healthy run from 1.25-1.80, for a chance at profit in excess of 44% on the day.



Other Standouts From Tuesday

There was significant excitement over the success of our options calls yesterday, but we still don’t want these other notable gainers from our watchlist to get lost in the shuffle:

Propanc Health Group Corp. PPCH – Trading Range: .0211-.03 – Max Gain: 42%

Microvision, Inc. MVIS – Trading Range: 3.07-3.55 – Max Gain: 16%

NovaBay Pharma, Inc. NBY – Trading Range: .56-.65 – Max Gain: 16%

Black Diamond, Inc. BDE – Trading Range: 8.45-9.84 – Max Gain: 16%


Side Note:

We are going to be sitting on the sidelines watching like hawks until we hear from Janet Yellen as the big FOMC meeting kicks off today. What she ultimately has to say will likely sway the markets one way or the other; we will wait to see which direction they’re going to go.

If the bull market remains intact, we’ll be looking to go long on SPY Calls.  Should the direction be a downward one, we can entertain UVXY and/or VIX Calls. Remember: Whatever way it plays out, we’ll want to stay in-the-money with our strike prices.


Extended Watchlist:
VTSS, RTRX, ATNM, RXDX, AEZS, ZQK

PROW, RNN & Extended Watchlist

Record-Setting ‘Green Rush’ Begins to Subside
Like all good things, the frenzied buying of countless pot stocks largely came to an end during yesterday’s session. It was a historic week; an overwhelming trend caused by sheer excitement over Colorado’s precedent-setting entry into the post-prohibition era, and we were happy to cover every step, taking profits along the way! Granted, the main wave of hysteria is now over, but our continued interest in the sector as a whole will not wane. As we stated previously, this story has only just begun to be written. Even as many of the huge runners we’ve tracked began to pull back, others maintained their trends, and still others came down to find support only to rebound and provide bounce opportunities. Rest assured, we will remain hot on the trail of any possible chance at added profits within this sector that has been so good to us for so long a time. For now, it’s time to shift gears and talk about some of our other interests that were forced to the back burner in all the excitement.

Progress Watch Corp. PROW

PROW has brought us some really impressive gains in the short time that we’ve been including it in our reports. When we first began talking about it (12/20/13, trading at .0065) we were especially interested in its tight share structure. That day, we said that the 50DMA rising sharply toward the 200DMA “should lead to a golden cross in the weeks and months ahead.”  That golden cross is now in progress as the stock ran into the close yesterday, attaining four cents, an increase of 515% off of the bottom we observed just twelve trading sessions ago.

As the value of the stock increases, we’re going to be looking for support levels to hold at areas of previous resistance. In the event of any pullbacks, we would like to see support hold at .025, and below that, .013, in order to remain bullish on PROW.


Rexhan Pharmaceuticals, Inc. RNN

Back on December 11th, we tagged RNN for the first time in our extended watchlist, and were rewarded with an intraday run of 26% from .4026 to  .5179. Even as marijuana stocks were breaking out over the past couple of days, we were still tracking this stock’s impressive run via our extended watchlists, and yesterday, saw a high of .765. That marks an increase of 90% from our observed low, a figure which is being pushed even higher this morning; pre-market trades have gone off as high as .929, so things could get very interesting from here. This spike seems to have been catalyzed by a recent press announcement from RNN.


The following PR was released under the headline: “RX-3117 has Shown Efficacy Against Gemcitabine-Resistant Human Cancer Cell Lines and a Broad-Spectrum of Anti-Cancer Activity “

ROCKVILLE, Md., Jan 08, 2014 (BUSINESS WIRE) — Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors. RX-3117 is a next-generation cancer cell specific drug candidate that possesses a broad spectrum of anticancer activity with reduced side effects. In an exploratory Phase I clinical trial conducted in Europe, RX-3117 demonstrated oral bioavailability, and safety and tolerability in cancer patients with solid tumors. >> FULL PR


Extended Watchlist:
CNAT, BBRY, IMMU, BLDP, NSPH, RTRX